4D Molecular Therapeutics Files Q1 2025 10-Q
Ticker: FDMT · Form: 10-Q · Filed: May 8, 2025 · CIK: 1650648
| Field | Detail |
|---|---|
| Company | 4d Molecular Therapeutics, INC. (FDMT) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, biotech, financials, gene therapy
TL;DR
**4D Molecular Therapeutics Q1 2025 10-Q filed. Financials and operations update.**
AI Summary
4D Molecular Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial performance and business operations, including details on its product candidates and collaborations. Specific financial figures and operational highlights from the first quarter of 2025 are detailed within the report.
Why It Matters
This filing provides investors with an update on 4D Molecular Therapeutics' financial health and strategic progress in the first quarter of 2025, crucial for understanding its ongoing development of gene therapies.
Risk Assessment
Risk Level: medium — Biotech companies like 4D Molecular Therapeutics are inherently risky due to the long and uncertain development cycles of their products and reliance on clinical trial success.
Key Numbers
- Q1 2025 — Reporting Period (The first quarter of 2025 financial and operational data is presented.)
- 2025-03-31 — End of Fiscal Period (The date as of which the financial statements are reported.)
- 2025-05-08 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- 4D Molecular Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250508 (date) — Filing date
- 5858 HORTON STREET #455 (location) — Company business address
- EMERYVILLE, CA (location) — Company business city and state
- UniQure Biopharma (company) — Mentioned in relation to a specific date
- Cystic Fibrosis Foundation (company) — Mentioned in relation to a funding agreement
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filed with the SEC?
This 10-Q was filed on May 8, 2025.
What is the company's primary business address?
The company's business address is 5858 Horton Street #455, Emeryville, CA 94608.
What is the SIC code for 4D Molecular Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for 4D Molecular Therapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Are there any specific collaborations or agreements mentioned in the filing data?
Yes, the filing data mentions 'UniQure Biopharma' and a 'Funding Agreement' with the 'Cystic Fibrosis Foundation' dated April 30, 2020.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding 4D Molecular Therapeutics, Inc. (FDMT).